News
ORMP
8.56
-2.39%
-0.21
We Think Oramed Pharmaceuticals (NASDAQ:ORMP) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Simply Wall St. · 08/01 11:40
Oramed Accomplishes 50 Percent Enrolment In Late-Stage Oral Insulin Study
Oramed Pharmaceuticals (NASDAQ: ORMP) has enrolled over 50 percent of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
Benzinga · 07/26 15:12
BRIEF-Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial
BRIEF-Oramed Reaches 50% Enrollment In Its Second Phase 3 Oral Insulin Trial
Reuters · 07/26 11:56
Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and randomized over 50% of the planned 450 pa...
PR Newswire · 07/26 11:55
Oramed Pharmaceuticals Enrolls Over 50% of Patients in Type-2 Diabetes Trial
Oramed Pharmaceuticals Enrolls Over 50% of Patients in Type-2 Diabetes Trial
MT Newswires · 07/26 10:13
Short Volatility Alert: Oramed Pharmaceuticals Inc.
On Wednesday, shares of Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) experienced volatile short activity. After the activity, the stock price went up +4.16% to $8.77. The overall sentiment for ORMP has been Bearish.
Benzinga · 07/21 15:20
Greenwich, Histogen top healthcare gainers; Can-Fite, Arcellx lead losers' pack
Gainers: Greenwich LifeSciences GLSI +41%. Histogen (HSTO) <font color="gr...
Seekingalpha · 07/12 14:00
Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present an in-person company overview and share the Com...
PR Newswire · 07/11 11:55
ORMP, SRAX and RVLP among mid-day movers
Gainers: Seritage Growth Properties (SRG) +72%. Ad...
Seekingalpha · 07/08 16:53
Oramed to report early-stage trial data for oral COVID-19 shot in 3Q
Oramed Pharmaceuticals (NASDAQ:ORMP), a clinical-stag...
Seekingalpha · 07/07 16:29
Oramed Letter to Shareholders
Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidr...
PR Newswire · 07/07 11:55
Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board.
PR Newswire · 06/01 11:55
Oramed granted U.S. combination therapy patent for oral insulin
Oramed Pharma (NASDAQ:ORMP) said on Tuesday that the United States Patent and Trademark Office had granted a patent for methods and compositions for treating diabetes. The patent is for methods and
Seekingalpha · 05/24 13:37
BRIEF-Oramed Granted U.S. Patent For Oral GLP-1 & Insulin For Diabetes Treatment
reuters.com · 05/24 12:11
Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that the United States Patent and Trademark Office has granted the...
PR Newswire · 05/24 12:10
Oramed Pharmaceuticals Secures US Patent for Oral Diabetes Treatment
MT Newswires · 05/24 10:16
Oramed to Present at H.C. Wainwright Global Investment Conference
Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person c...
PR Newswire · 05/18 11:55
--Aegis Capital Adjusts Price Target for Oramed Pharmaceuticals to $30 From $35, Maintains Buy Rating
MT Newswires · 05/16 10:20
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 807 companies reached new 52-week lows.
Benzinga · 05/11 16:28
Shareholders in Oramed Pharmaceuticals (NASDAQ:ORMP) have lost 58%, as stock drops 22% this past week
Investing in stocks comes with the risk that the share price will fall. And there's no doubt that Oramed...
Simply Wall St. · 05/10 11:12
More
Webull provides a variety of real-time ORMP stock news. You can receive the latest news about Oramed Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About ORMP
Oramed Pharmaceuticals Inc. is a pharmaceutical company. It is engaged in the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. Its pipeline products are ORMD-0801 Type 1, ORM-0801 Type 2 and ORMD-0901. Its flagship product, ORMD-0801, is an orally ingestible insulin capsule. It is anticipated for use as a complementary agent to insulin injections in the treatment of Type I diabetes Mellitus (T1DM) and T2Dm disease. This treatment regimen should allow for fewer daily injections and a lower frequency of blood glucose fluctuations in cases of unstable and brittle T1DM. Glucagon-like peptide-1 (GLP-1) is an incretin hormone, which is a type of gastrointestinal hormone that stimulates the secretion of insulin from the pancreas. The Company's other product is ORMD-0901, an orally ingestible GLP-1 capsule.